ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Pharmaceuticals

South Korea's biotech ambitions overshadowed by scandals

Clinical failures and fraud allegations overshadow industry touted as next frontier

An accounting scandal has rocked Samsung Biologics, which was supposed to be a new cash cow for South Korea's Samsung group. (Courtesy of Samsung Biologics)

SEOUL -- Investors cheered when Samsung Biologics announced Wednesday that its operating profit for the previous quarter had more than doubled on the year. Its share price accordingly shot up -- despite South Korea's financial regulators warning just a week before that biomedicine remains a risky investor bet.

That rare warning was prompted by a series of scandals and setbacks for an industry that was supposed to represent the next frontier for South Korea's economy.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more